GLP-1 receptor agonists for weight reduction in people living with obesity
Wegovy highlights of prescribing information, Food and Drug Administration (2024) Adipex-P highlights of prescribing information, Food and Drug Administration (2012) FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, Food and Drug Administration (2024) Medications for obesity management: Effectiveness and value, Journal of Managed Care and Specialty Pharmacy (2023) A narrative review of approved and emerging anti-obesity medications, Saudi Pharmaceutical Journal (2023) Label: Wegovy, DailyMed (2024) Label: ADIPEX-P- phentermine hydrochloride tablet, DailyMed (2024) GLP-1 receptor agonists and the risk of thyroid cancer, Diabetes Care (2023) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
You can reach out to us through our website's contact form or give us a call during our business hours
Accessed December 5, 2025
In Qsymia trials, patients on Qsymia tended to lose about 8% to 10% of their weight in 56 weeks (about 13 months)
Step 2: Develop a Transition Plan Your healthcare provider will create a personalized transition plan based on your health status and current medication regimen